SCA
PFE icon

Sassicaia Capital Advisers’s Pfizer PFE Stock Holding History

Sassicaia Capital Advisers’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-907,923
Closed -$23.1M – 47
2025
Q3 		$23.1M Buy
+907,923
New +$22.4M 10.31% 2
2023
Q4 		– Sell
-7,500
Closed -$249K – 16
2023
Q3 		$249K Buy
+7,500
New +$265K 11.7% 4

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $146B AUM 55.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Sassicaia Capital Advisers's PFE Position: Q4 2025 in Review

Sassicaia Capital Advisers sold out of Pfizer (PFE) in Q4 2025, closing a stake of 907,923 shares — an estimated $23.1M sold.

Sassicaia Capital Advisers first reported a position in PFE in Q3 2023 and held it in 2 quarters. The position peaked at $23.1M in Q3 2025. 2,914 funds tracked by Wall St. Rank hold PFE as of Q4 2025.

  • Sassicaia Capital Advisers reported no remaining Pfizer position as of Q4 2025 after selling out during the quarter.
  • Sassicaia Capital Advisers sold 907,923 Pfizer shares in Q4 2025, an estimated $23.1M.
  • Sassicaia Capital Advisers first reported a position in Pfizer in Q3 2023 and held it in 2 quarters.
  • Sassicaia Capital Advisers's Pfizer position peaked at $23.1M in Q3 2025.
  • 2,914 funds tracked by Wall St. Rank held Pfizer as of Q4 2025.

Based on Sassicaia Capital Advisers's 13F filing for Q4 2025, filed 13 Feb 2026.